Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 1 |
2023 | 2 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2- advanced breast cancer.
Ther Adv Med Oncol. 2023 Dec 14;15:17588359231216095. doi: 10.1177/17588359231216095. eCollection 2023.
Ther Adv Med Oncol. 2023.
PMID: 38107828
Free PMC article.
Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2.
Cameron D, Kumar Sharma V, Biswas C, Clarke C, Chandiwana D, Pathak P.
Cameron D, et al. Among authors: kumar sharma v.
J Med Econ. 2023 Jan-Dec;26(1):357-365. doi: 10.1080/13696998.2023.2182051.
J Med Econ. 2023.
PMID: 36797664
Free article.
Item in Clipboard
Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers.
Shah NR, Bhor M, Latremouille-Viau D, Kumar Sharma V, Puckrein GA, Gagnon-Sanschagrin P, Khare A, Kumar Singh M, Serra E, Davidson M, Xu L, Guerin A.
Shah NR, et al. Among authors: kumar sharma v.
J Med Econ. 2020 Nov;23(11):1345-1355. doi: 10.1080/13696998.2020.1813144. Epub 2020 Sep 9.
J Med Econ. 2020.
PMID: 32815766
Free article.
Item in Clipboard
Cite
Cite